Director/PDMR Shareholding

RNS Number : 7997Q
Hikma Pharmaceuticals Plc
08 June 2018
 

 

Hikma Pharmaceuticals PLC - EIP Awards

 

LONDON, 8 June 2018: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)
(LEI: 549300BNS685UXH4JI75)
announces that the Remuneration Committee has made the following nil cost option under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to a Person Discharging Managerial Responsibility ("PDMR") of the Company.

The Award under the EIP was made on 7 June 2018 at a price of 1,035 pence per Ordinary Share (being the average price for the 30-day period prior to 31 December 2017, in accordance with the EIP rules) as follows:

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Surendera Tyagi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Surendera Tyagi

2

Reason for the notification

a)

Position/status

Chief Scientific Officer and Global Head of R&D

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

The Company granted the named individual above a nil-cost option award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years, subject to continued employment.

c)

Price(s) and volume(s)

Price(s): £10.35

Volume(s): 28,818

d)

Aggregated information

N/A

e)

Date of the transaction

7 June 2018

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBGGDLLSGBGII
UK 100

Latest directors dealings